Entrada Therapeutics, Inc. (TRDA)
USD 17.1
(-7.32%)
USD 17.1
(-7.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 129.01 Million | - | - | - | - |
| Cost of Revenue | 99.88 Million | 1.89 Million | 1.11 Million | 326 Thousand | 104 Thousand |
| Gross Profit | 29.12 Million | -1.89 Million | -1.11 Million | -326 Thousand | -104 Thousand |
| Operating Expenses | 132.17 Million | 97.24 Million | 51.12 Million | 26.66 Million | 11.82 Million |
| Selling, General and Administrative Expenses | 32.29 Million | 30.63 Million | 15.2 Million | 5.56 Million | 3.6 Million |
| Research and Development Expenses | 99.88 Million | 66.6 Million | 35.92 Million | 21.1 Million | 8.21 Million |
| Other Expenses | - | - | - | - | 6.27 Million |
| Cost and Expenses | 132.17 Million | 97.24 Million | 51.12 Million | 26.66 Million | 11.82 Million |
| Operating Income | -3.16 Million | -97.24 Million | -51.12 Million | -26.66 Million | -11.82 Million |
| Interest Expense | - | 2.63 Million | - | - | - |
| Income Tax Expense | 18.74 Million | -7.15 Million | -1.08 Million | -144 Thousand | -451 Thousand |
| Earnings before Tax | 12.05 Million | -94.61 Million | -51.15 Million | -26.52 Million | -5.1 Million |
| Net Income | -6.68 Million | -87.45 Million | -50.07 Million | -26.37 Million | -4.64 Million |
| Earnings Per Share Basic | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Earnings Per Share Diluted | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Weighted Average Shares Outstanding | 33.05 Million | 31.29 Million | 31.22 Million | 31.24 Million | 31.24 Million |
| Weighted Average Shares Outstanding (Diluted) | 33.05 Million | 31.29 Million | 31.22 Million | 31.24 Million | 31.24 Million |
| Gross Margin | 0.23 | - | - | - | - |
| EBIT Margin | -0.00 | - | - | - | - |
| Profit Margin | -0.05 | - | - | - | - |
| EBITDA | -321 Thousand | -95.35 Million | -50.01 Million | -26.34 Million | -11.72 Million |
| Earnings Before Tax Margin | -0.02 | - | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 19.57 Million | 94.69 Million | 59.12 Million | 41.84 Million | 129.01 Million | 43.73 Million |
| Cost of Revenue | - | 900 Thousand | 934 Thousand | 736 Thousand | 2.84 Million | 800 Thousand |
| Gross Profit | 19.57 Million | 93.79 Million | 58.18 Million | 41.11 Million | 126.17 Million | 42.93 Million |
| Operating Expenses | 41.22 Million | 40.37 Million | 37.07 Million | 36.2 Million | 129.33 Million | 29.72 Million |
| Selling, General and Administrative Expenses | 9.97 Million | 9.23 Million | 9.39 Million | 8.65 Million | - | 7.53 Million |
| Research and Development Expenses | 31.25 Million | 31.13 Million | 27.67 Million | 27.55 Million | - | 22.19 Million |
| Other Expenses | - | -32.03 Million | - | - | - | - |
| Cost and Expenses | 41.22 Million | 41.27 Million | 38 Million | 36.94 Million | 132.17 Million | 29.72 Million |
| Operating Income | -21.65 Million | 53.42 Million | 21.11 Million | 4.9 Million | -3.16 Million | 14.01 Million |
| Interest Expense | - | - | - | -4.44 Million | - | - |
| Income Tax Expense | -1.86 Million | 2.75 Million | 1.83 Million | 18.74 Million | 18.74 Million | -17.39 Million |
| Earnings before Tax | -15.89 Million | 57.78 Million | 25.32 Million | 9.19 Million | 12.05 Million | 18.06 Million |
| Net Income | -14.03 Million | 55.03 Million | 23.49 Million | -9.54 Million | -6.68 Million | 35.46 Million |
| Earnings Per Share Basic | -0.35 | 1.61 | 0.70 | -0.29 | - | 1.07 |
| Earnings Per Share Diluted | -0.35 | 1.55 | 0.68 | -0.29 | - | 1.02 |
| Weighted Average Shares Outstanding | 40.62 Million | 34.18 Million | 33.49 Million | 33.36 Million | 33.05 Million | 33.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 40.62 Million | 35.5 Million | 34.79 Million | 33.36 Million | 33.05 Million | 34.77 Million |
| Gross Margin | 1.00 | 0.99 | 0.98 | 0.98 | 0.98 | 0.98 |
| EBIT Margin | -1.11 | 0.57 | 0.37 | 0.13 | - | 0.32 |
| Profit Margin | -0.72 | 0.58 | 0.40 | -0.23 | -0.05 | 0.81 |
| EBITDA | -21.65 Million | 54.32 Million | 22.04 Million | 5.64 Million | - | 14.01 Million |
| Earnings Before Tax Margin | -1.11 | 0.56 | 0.36 | 0.12 | -0.02 | 0.32 |
0LPE
4308
VIAAY
EME
BOLT
XELA